Mathematical modelling of spatio-temporal phenomana in tumour immunology

Lecture Notes in Mathematics

Volumn 1872, Issue , 2005, Pages 131-183

  Chaplain, Mark ^a   Matzavinos, Anastasios ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748847903     PISSN: 00758434     EISSN: None     Source Type: Book Series    
DOI: 10.1007/11561606_4     Document Type: Article

References (141)

1. Abbas, A., Lichtman, A. & Pober, J. (2000), Cellular and Molecular Immunology, 4th edn, W.B. Saunders Company.
2. Adam, J. (1993), "The dynamics of growth-factor-modified immune response to cancer growth: One dimensional models", Math. Comp. Modell. 17, 83-106.
3. Adam, J. & Bellomo, N., eds (1997), A Survey of Models for Tumor-Immune System Dynamics, Birkhaüser, Boston.
4. Alsabti, A. (1978), "Tumour dormant state", Tumour Res. 13(1), 1-13.
5. Ambrosi, D., Bellomo, N. & Preziosi, L. (2002), "Modelling tumor progression, heterogeneity, and immune competition", J. Theor. Medicine 4, 51-65.
6. Angelis, E. D., Delitala, M., Marasco, A. &. Romano, A. (2003), "Bifurcation analysis for a mean field modelling of tumor and immune system competition", Math. Comp. Modelling 37, 1131-1142.
7. Annichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M. & Parmiani, G. (1993), "Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients", J. Exp. Med. 177, 989-998.
8. Baldwin, R. (1955), "Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors", Br. J. Cancer 9, 652-656.
9. Bar-Eli, M. (1999), "Role of interleukin-8 in tumor growth and metastasis of human melanoma", Pathobiology 67(1), 12-18.
10. Barz, D., Goppelt, M., Schrimacher, V. & Reach, K. (1985), "Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (Esb)", Bioch. biophys. Acta 814, 77-84.
11. Bellorno, N. &: Preziosi, L. (2000), "Modelling and mathematical problems related to tnrnor evolution and its interaction with the immune system", Math. Comp. Modelling 32, 413-452.
12. Bellomo, N., Bellouquid, A. & Angelis, E. D. (2003), "The modelling of the immune competition by generalized kinetic (Boltzmann) models: Review and research perspectives", Math. Comp. Modelling 37, 65-86.
13. Bellomo, N., Firmani, B. &, Guerri, L. (1999), "Bifurcation analysis for a non-linear system of integro-difierential equations modelling tumor-immune cells competition", Appl. Math. Letters 12, 39-44.
14. Berezhnaya, N. M., Yakimovich, L. V., Kobzar, R. A. S., Lyulkin, V. D. & Papivets, A. Y. (1986), "The effect of interleukin-2 on proliferation of expiants of malignant soft-tissue tumours in diffusion chambers", Experimental Oncology 8, 39-42.
15. Bohman, Y. (1976), Metastases of corpus uterus cancer, Leningrad: Medicine.
16. Breslow, N., Chan, C., Dhom, G., Drury, R., Franks, L., Gellei, B., Lee, Y., Lundberg, S., Sparke, B., Sternby, N. &: Tulinius, H. (1977), "Latent carcinoma of prostate at autopsy in seven areas", Intern. J. Cancer 20(5), 680-688.
17. Brocker, E., Zwaldo, G., Holzmann, B., Macher, E. & Sorg, C. (1988), "Inammatory cell infiltrates in human melanoma at different stages of tumour progression", Int. J. Cancer 41, 562-567.
18. Brunner, K., Mauel, J., Cerottini, J. &: Chapuis, B. (1968), "Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro, inhibition by isoantibody and by drugs", Immunology 14, 181-196.
19. Burnet, F. M. (1970), "The concept of immunological surveillance", Progress in Experimental Tumor Research 13, 1-27.
20. Butterfield, L., Koh, A., Meng, W., Vollmer, C., Ribas, A., Dissette, V., Lee, E., Glaspy, J., McBride, W. &: Economou, J. (1999), "Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein", Cancer Res. 59, 3134-3142.
21. Cairns, C., Gordon, J., Li, F., Baca-Estrada, M., Moyana, T. & Xiang, J. (2001), "Lympho taktin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor", J Immunol. 167(1), 57-65.
22. Chaplain, M., Kuznetsov, V., James, Z. &: Stepanova, L. (1998), Spatiotemporal dynamics of the immune system response to cancer, in M. A. Horn, G. Simonett & G. Webb, eds, "Mathematical Models in Medical and Health Sciences", Vanderbilt University Press, pp. 1-20.
23. Clark, W. (1991), "Tumour progression and the nature of cancer", Brit. J. Cancer 64, 631-644.
24. Clark, W., Elder, D. & Vanhorn, M. (1986), "The biologic forms of malignant melanoma", Human Pathology 17, 443-450.
25. Coulie, P., Brichard, V., Pel, A. V., Wölfel, T., Schneider, J., Traversari, C., Mattel, S., Plaen, E. D., Lurquin, C., Szikora, J. et al. (1994), "A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas", J. Exp. Med. 180, 35-42.
26. Cowan, D., Hicks, K. & Wilson, W. (1996), "Multicellular membranes as an in vitro model for extravascular diffusion in tumours", Br J Cancer Suppl. 27, S28-S31.
27. den Eynde, B. V. & van der Bruggen, P. (1997), "T cell defined tumor antigens", Current Opinion in Immunology 9, 684-693.
28. Deweger, R., Wilbrink, B., Moberts, R., Mans, D., Oskam, R. & den Otten, W. (1987), "Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice", Cancer Immun. Immunotherapy 24, 1191-1192.
29. Doherty, P., dunlop, M., Parish, C. & Zinkernagel, R. (1976), "Inammatory process in rimrine lyrnphocytic choriomeningitis is maximal in H-2K or H-2D compatible interactions", J. Immunol. 117, 187-190.
30. Drasdo, D. & Höhme, S. (2003), "Individual-based approaches to birth and death in avascular tumours", Math. Comput. Model. 37, 1163-1175.
31. Durand, R. &: Sutherland, R. (1984), "Growth and cellular characteristics of multicell spheroids", Recent Results in Cancer Research 95, 24-49.
32. Fernendez, N., Duffour, M., Perricaudet, M. et al. (1998), "Active specific T-cell based immunotherapy for cancers: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects", Cytokines Cell. Mol. Ther. 4(1), 53-65.
33. Finn, O., Jerome, K., Henderson, R. et al. (1995), "MUC-1 epithelial tumor mucin-based immunity and cancer vaccines", Immunol. Rev. 145, 61-89.
34. Fisk, B., Blevins, T., Wharton, J. &: Ioannides, C. (1995), "Identification of an immunodorninant peptide of HEH-2/neu protooricogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines", J. Exp. Med. 181, 2109-2117.
35. Folkman, J. (1985), "How is blood-vessel growth regulated in normal and neoplastic tissue", Proc. Amer. Assoc. Cancer Res. 26, 384-385.
36. Forni, G. (1996), "Tumor-host relationship: the viewpoint of an immunologist towards applied mathematicians", Mathl. Comput. Modelling 23(6), 89-94.
37. Forni, G., Parmiani, G., Guarini, A. & Foa, R. (1994), "Gene transfer in tumour therapy", Annals Oncol. 5, 789-794.
38. Friedl, P., Noble, P. & Zanker, K. (1995), "T-Lymphocyte locomotion in a 3-dimensional collagen matrix - expression and function of cell-adhesion molecules", J. Immunol. 154, 4973-4985.
39. Gatenby, R. (1995), "Models of tumor-host intearcation as competing populations: Implications for tumor biology and treatment", J. theor. Biol. 176, 447-455.
40. Gatenby, R. (1996), "Application of competition theory to tumour growth: Implications for tumour biology and treatment", European Journal of Cancer 32A, 722-726.
41. Ghiso, J. A. (2002), "Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo", Oncogene 21(16), 2513-2524.
42. Giovarelli, M., Cappello, P., Forni, G., Salcedo, T., Moore, P., LeFleur, D., Nardelli, B., Carlo, E., Lollini, P., Ruben, S., Ullrich, S., Garotta, G. & Musiani, P. (2000), "Tumor rejection and immune memory elicited by locally released LEG chemokine are associated with an impressive recruitment of APCs, lymphocytes and granulocytes", J Immunol. 164(6), 3200-3206.
43. Greten, T. & Jaffee, E. (1999), "Cancer vaccines", J. Clin. Oncol. 17(3), 1047-1060.
44. Hammarstrom, S. (1999), "The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues", Semin. Cancer Biol. 9, 67-81.
45. Hellström, K. & Hellström, I. (1969), "Cellular immunity against tumor antigens", Adv. Cancer Res. 12, 167-223.
46. Hersey, P. (1997), "Melanoma vaccines. Prospects for the treatment of melanoma", Expert Op., Invest. Drugs 6, 267-277.
47. Hersey, P. & Marincola, F. (2002), Immunotherapy of Cancer, in G. Parmiani & M. Lotze, eds, "Tumor Immunology: Molecularly Defined Antigens and Clinical Applications", Taylor & Francis, pp. 117-175.
48. Hesketh, R. (1997), The Oncogene and Tumor Suppressor Genes Facts Book, 2nd edn, Academic Press.
49. Hodge, J. (1996), "Carcinoembryonic antigen as a target for cancer vaccines", Cancer Immunol. Immunother. 43, 127-134.
50. Holmberg, L. & Baum, M. (1996), "Work on your theories!", Nat. Med. 2(8), 844-846.
51. Ikeda, H., Lethé, B., Lehmann, F., Baren, N. V., Baurain, J., Smet, C. D., Chambost, H., Vitale, M., Moretta, A., Boon, T. & Coulie, P. (1997), "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor", Immunity 6, 199-208.
52. Ioannides, C. & Whiteside, T. (1993), "T-cell recognition of human tumours - implications for molecular immunotherapy of cancer", Clin. Immunol. Immunopath. 66, 91-106.
53. Jaaskelainen, J., Maenpaa, A., Patarroyo, M., Gahmberg, C., Somersalo, K., Tarkkanen, J., Kallio, M. & Timonen, T. (1992), "Migration of recombinant IL-2-activated T-cells and natural killer cells in the intercellular space of human H-2 gliorna spheroids in vitro - a study on adhesion molecules involved", J. Immunol. 149, 260-268.
54. Kast, W. & Melief, C. (1991), "Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumors and peptide-MHC binding", Int. J. Cancer Suppl. 6, 90-94.
55. Kast, W., Offringa, R., Peters, P., Voordouw, A., Meloen, R., van der Eb, A. & Melief, C. (1989), "Eradication of adenovirus El-induced tumors by E1A specific cytotoxic T lymphocytes", Cell 59, 603-614.
56. Kawakami, Y., Eliyahu, S., Delgado, C., Robbins, P., Rivoltini, L., Topalian, S., Miki, T. &: Rosenberg, S. (1994), "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrated into tumor", Proc. Natl. Acad. Sci. USA 91, 3515-3519.
57. Kawakami, Y., Nishimura, M., Restifo, N., Topalian, S., O"Neil, B., Shilyarisky, J., Yannelli, J. &: Rosenberg, S. (1993), "T-cell recognition of humanmelanoma antigens", J. Immunotherapy 14, 88-93.
58. Kelly, C., Leek, R., Byrne, H., Cox, S., Harris, A. & Lewis, C. (2002), "Modelling macrophage infiltration into avascular tumours", J. Theor: Med. 4, 21-38.
59. + helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens", J. Exp. Med. 169, 457-467.
60. Klein, G., Sjogren, H., Klein, E. & Hellström, K. (1960), "Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochtonous host", Cancer Res. 20, 1561-1572.
61. Kuznetsov, V. (1979), Dynamics of cellular immune anti-tumor reactions. I. Synthesis of a multi-level model, in V. Fedorov, ed., "Mathematical Methods in the Theory of Systems", Frunze: Kyrghyz State University, pp. 57-71. (In Russian).
62. Kuznetsov, V. (1991), "A mathematical model for the interaction between cytotoxic lymphocytes and tumor cells. Analysis of the growth, stabilization and regression of the B cell lymphoma in mice chirneric with respect to the major histocompatibility complex", Biomed. Sci. 2(5), 465-476.
63. Kuznetsov, V. & Knott, G. (2001), "Modeling tumor regrowth and immunotherapy", Math. Comput. Modelling 33, 1275-1287.
64. Kuznetsov, V. &: Puri, R. (1999), "Kinetic analysis of the high affinity forms of interleukin (IL)-13 receptors: Suppression of IL-13 binding by IL-2 receptor γ chain", Biophysical J. 77, 154-172.
65. Kuznetsov, V., Makalkin, I., Taylor, M. & Perelson, A. (1994), "Nonlinear dynamics of immunogenic tumours: Parameter estimation and global bifurcation analysis", Bull. Math. Biol. 56, 295-321.
66. Kuznetsov, V., Zhivoglyadov, V. & Stepanova, L. (1993), "Kinetic approach and estimation of the parameters of cellular interaction between the immune system and a tumour", Arch. Immunol. Therap. Exper. 41, 21-32.
67. Kwok, G., Cole, S. & Liao, S. (1988), "Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids", Cancer Res. 48(7), 1856-1863.
68. Kyle, A., Chan, C. & Minchinton, A. (1999), "Characterization of threedimensional tissue cultures using electrical impedance spectroscopy", Biophys J. 76(5), 2640-2648.
69. Lee, J., Moran, J., Fenton, B., Koch, C., Frelinger, J., Keng, P. & Lord, E. (2000a), "Alteration of tumour response to radiation by interleukin-2 gene transfer", Br J Cancer 82(4), 937-944.
70. Lee, L., Hellendall, R., Wang, Y., Haskilla, J., Mukaida, N., Matsushima, K. & Ting, J. (2000b), "IL-8 reduces tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration", J Immunol. 164(5), 2769-2775.
71. Lefever, R. & Erneaux, T. (1984), On the growth of cellular tissues under constant and uctuating environmental conditions, in W. Ross &: A. Lawrence, eds, "Nonlinear Electrodynamics in Biological Systems", Plenum Publishing Corporation, pp. 287-305.
72. Lodge, P., Ghilds, R., Monahan, S. et al. (1999), "Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells", J. Immunother. 22(4), 346-355.
73. Loeffler, D. & Ratner, S. (1989), "In vivo localization of lymphocytes labeled with low concentrations of HOECHST-33342", J. Immunol. Meth. 119, 95-101.
74. Loeffler, D., Heppner, G. & Lord, E. (1988), "Inuence of hypoxia on T lymphocytes in solid tumours", Proc. Amer. Assoc. Cancer Res. 29, p378.
75. Lord, E. & Burkhardt, G. (1984), "Assessment of in situ host immunity to syngeneic tumours utilizing the multicellular spheroid model", Cell. Immunol. 85, 340-350.
76. Lord, E. & Nardella, G. (1980), "The multicellular tumour spheroid model. 2. characterization of the preliminary allograft response in unsensitized mice", Transplantation 29, 119-124.
77. Lowy, D. & Schiller, J. (1999), "Papillomaviruses: prophylactic vaccine prospects", Biochim. Biophys. Acta 1423(1), M1-M8.
78. Lustgarten, J., Theobald, M., Labadie, O., LaFace, D., Peterson, P., Disis, M., Gheever, M. & Sherman, L. (1997), "Identification of Her-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8", Hum. Immunol. 52, 109-118.
79. MacSween, R. &, Whaley, K., eds (1992), Muir"s Textbook of Pathology, 13th edn, Edward Arnold, London.
80. Marušić, M., Ž. Bajzer, Vuk-Pavlović, S. & Freyer, J. (1994a), "Analysis of the growth of multicellular tumour spheroids by mathematical models", Cell Prolif. 27, 73-94.
81. Marušić, M., Ž. Bajzer, Vuk-Pavlović, S. & Freyer, J. (1994b), "Tumour growth in vivo and as multicellular spheroids compared by mathematical models", Bull. Math. Biol. 56, 617-631.
82. Matzavinos, A. & Chaplain, M. (2004), "Travelling wave analysis of a model of the immune response to cancer", C.R. Biologies 327, 995-1008.
83. Matzavinos, A., Chaplain, M. & Kuznetsov, V. (2004), "Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour", Mathematical Medicine and Biology: A Journal of the IMA 21, 1-34.
84. Matzavinos-Toumasis, A. (2004), Mathematical modelling of the spatiotemporal response of cytotoxic T-lymphocytes to a solid tumour, PhD thesis, University of Dundee.
85. Melief, C., Annels, N., Dunbar, R. et al. (1998), "Protective T-cell responses against tumours", Res. Immunol. 149(9), 877-879.
86. Merlo, G., Siddiqui, J., Cropp, C. et al. (1989), "Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas", Cancer Res. 49(24), 6966-6971.
87. Murphy, C. & Newsholme, P. (1999), "Macrophage-mediated lysis of a betacell line, tumour necrosis factor-alpha, release from bacillus Calmette- Guerin (BCG)-activated murine macrophges and interleukin-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism", Clin Sci (Lond) 96(1), 89-97.
88. Murphy, G., Elgamal, A., Su, S. et al. (1998), "Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen", Cancer 83(11), 2259-2269.
89. Naurnov, G., MacDonald, I., Weinmeister, P., Kerkvliet, N., Nadkarni, K., Wilson, S., Morris, V., Groom, A. & Chambers, A. (2002), "Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy", Cancer Res. 62(7), 2162-2168.
90. Nesvetov, A. &: Zhdanov, A. (1981), "Relationship of the morphology of the immune response and the histological structure of tumours in stomach cancer patients", Voprosy Onkologii 27, 25-31.
91. Nomiyama, H., Hieshima, K., Nakayarna, T., Sakaguchi, T., Fujisawa, R., Tanase, S., Nishiura, H., Matsuno, K., Takamori, H., Tabira, Y., Yamamoto, T., Miura, R. & Yoshie, O. (2001), "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes", Int Immunol. 13(8), 1021-1029.
92. Nosten, F., Luxemburger, C., Kyle, D., Ballon, W., Wittes, J., Wah, E., Chongsuphajaisiddhi, T., Gordon, D., White, N., Sadoff, J. & Heppner, D. (1996), "Randomized double-bind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand", Lancet 348, 701-707.
93. Nowak, M. & May, R. (2000), Virus Dynamics: Mathematical Principles of Immunology and Virology, Oxford University Press.
94. O'Connell, J., Bennett, M., O'Sullivan, G., Collins, J. & Shanahan, F. (1999), "The Fas counterattack: cancer as a site of immune privilege", Immunol. Today 20(1), 46-50.
95. Old, L., Boyse, E., Clarke, D. & Carswell, E. (1962), "Antigenic properties of chemically induced tumors", Ann. N. Y. Acad. Sci. 101, 80-106.
96. Owen, M. & Sherratt, J. (1997), "Pattern formation and spatio-temporal irregularity in a model for macrophage-tumour interactions", J. Theor. Biol. 189, 63-80.
97. Owen, M. & Sherratt, J. (1998), "Modelling the macrophage invasion of tumours: Effects on growth and composition", IMA J. Math. Appl. Med. Biol. 15, 165-185.
98. Owen, M. & Sherratt, J. (1999), "Mathematical modelling of macrophage dynamics in tumours", Math. Models Meth. Appl. Sci. 9, 513-539.
99. Pardoll, D. (1998), "Cancer vaccines", Nat Med. 4(5 Suppl), 525-531.
100. Parrniani, G. & Lotze, M., eds (2002), Tumor Immunology: Molecularly Defined Antigens and Clinical Applications, Vol. 1 of Tumor Immunology and Immunotherapy Series, Taylor &: Francis.
101. Perelson, A. & Weisbuch, G. (1997), "Immunology for physicists", Reviews of Modern Physics 69(4), 1219-1267.
102. Plata, F., Langlade-Demoyen, P., Abastado, J., Berbar, T. & Kourilsky, P. (1987), "Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo", Cell 48, 231-240.
103. Ponnighaus, J., Fine, P., Sterne, J., Wilson, R., Msosa, E., Gruer, P., Jenkins, P., Lucas, S., Liomba, N. & Bliss, L. (1992), "Efficacy of BOG vaccine against leprosy and tuberculosis in northern Malawi", Lancet, 339, 636-639.
104. Prehn, R. (1994), "Stimulatory effects of immune reactions upon the growths of untransplanted tumours", Cancer Res. 54, 908-914.
105. Prehn, R. &: Main, J. (1957), "Immunity to methylcholanthrene- induced sarcomas", J. Natl. Cancer Inst USA 18, 759-778.
106. Prigogine, I. & Lefever, R. (1980), "Stability problems in cancer growth and nucleation", Comp. Biochem. Physiol. 67, 389-393.
107. Puri, R. &, Siegel, J. (1993), "Interleukin-4 and cancer therapy", Cancer Invest. 11, 473-486.
108. Ratner, S. & Heppner, G. (1986), "Mechanisms of lymphocyte traffic in neoplasia", Anticancer Res. 6, 475-482.
109. Reisenberger, K., Egarter, C., Vogl, S., Sternberger, B., Kiss, H. & Husslein, P. (1996), "The transfer of interleukin-8 across the human placenta perfused in vitro", Obstet Gynecol 87(4), 613-616.
110. Resnitzky, P., Bustan, A., Peled, A. &, Marikovsky, Y. (1988), "Variations in surface charge distribution of leukemic and nonleukemic transformed cells", Leuk. Res. 12, 315-320.
111. Ressing, M., de Hong, J., Brandt, R. et al. (1999), "Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma", Eur. J. Immunol. 29(4), 1292-1303.
112. Retsky, M., Wardwell, R., Swartzendruber, D. & Headley, D. (1987), "Prospective computerized simulation of breast-cancer - comparison of computerpredictions with 9 sets of biological and clinical data", Cancer Res. 47, 4982-4987.
113. Bobbins, P. (2002), Immune Recognition of Cancer - Tumor Antigens, in G. Parmiani & M. Lotze, eds, "Tumor Immunology: Molecularly Defined Antigens and Clinical Applications", Taylor & Francis, pp. 11-46.
114. Robbina, P., el Gamil, M., Li, Y., Topalian, S., Rivoltini, L., Sakaguchi, B., Appella, E., Kawakami, Y. & Rosenberg, S. (1995), "Cloning of a new gene encoding an antigen recognized by melanoma.-specific HLA-A24- restricted tumorinfiltrating lymphocytes", J. Immunol. 154, 5944-5950.
115. Rosenberg, S. (1999), "A new era for cancer immunotherapy based on the genes that encode cancer antigens", Immunity 10(3), 281-287.
116. Rothstein, T., Mage, M., Mond, J. &, McHugh, L. (1978), "Guinea pig antiserum to mouse cytotoxic T-lymphocytes and their precursor", J. Immunol. 120, 209-215.
117. Ruiz-Cabello, F. & Garrido, F. (2002), Tumor evasion of immune system, in G. Parmiani & M. T. Lotze, eds, "Tumor Immunology: Molecularly Defined Antigens and Clinical Applications", Taylor & Francis, pp. 177-203.
118. Salgaller, M. (1997), "Monitoring of cancer patients undergoing active or passive immunotherapy", J. Immunother. 20, 1-14.
119. Satyamoorthy, K., Li, G., Vaidya, B., Kalabis, J. & Herlyn, M. (2002), "Insulin-like growth factor-I-induced migration of melanoma, cells is mediated by interleukin-8 induction", Cell Growth Differ. 13(2), 87-93.
120. Schlom, J. & Abrams, S. (2000), Tumor Immunology, in R. Bast, D. Kufe, R. Pollock, R. Weichselbaum, J. Holland & E. F. III, eds, "Cancer Medicine", 5th edn, BC Decker, pp. 153-167.
121. Schwartzentruber, D., S.L. Topalian, Mancini, M. & Rosenberg, S. (1991), "Specific release of granulocyte-macrophage colony-stimulating factor, tumour necrosis factor-α and IFN-γ by human tumour-infiltrating lymphocytes after autologous tumour stimulation", J. Immunol. 146, 3674-3681.
122. Shampine, L. & Reichelt, M. (1997), "The MATLAB ODE suite", SIAM J. Sci. Comput. 18(1), 1-22.
123. Sherbet, G. (1989), "Membrane uidity and cancer metastasis", Expl. Cell. Biol. 57, 198-205.
124. Sherratt, J., Lewis, M. & Fowler, A. (1995), "Ecological chaos in the wake of invasion", Proc. Natl. Acad. Sci. USA 92, 2524-2528.
125. Siu, H., Vitetta, E., May, R. & Uhr, J. (1986), "Tumour dormancy, regression of BCL tumour and induction of a dormant tumour state in mice chimeric at the major histocompatibility complex", J. Immunol. 137, 1376-1382.
126. Sordat, B., MacDonald, H. & Lees, R. (1980), "The multicellular spheroid as a model tumour allograft. 3. morphological and kinetic analysis of spheroid infiltration and destruction", Transplantation 29, 103-112.
127. Sozzani, S., Luini, W., Molino, M., Jilek, P., Bottazzi, B. & Cerletti, C. (1991), "The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine", J Immunol. 147, 2215-2221.
128. Sutherland, R. (1988), "Cell and environment interactions in tumor microregioris: the multicell spheroid model", Science 240(4849), 177-184.
129. Suzuki, Y., Liu, C., Chen, L., Bennathan, D. &. Wheelock, E. (1987), "Immune regulation of the L5178Y marine tumour dormant state. 2. Interferon gamma requires tumour necrosis factor to restrain tumour cell growth in peritoneal cell cultures from tumour dormant mice", J. Immunol. 139, 3146-3152.
130. Tanaka, Y., Tevethia, M., Kalderon, D., Smith, A. & Tevethia, S. (1988), "Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 antigen", Virology 162, 427-436.
131. Tjoa, B., Elgamal, A. &: Murphy, G. (1999), "Vaccine therapy for prostate cancer", Urol. Clin. North Am. 26(2), 365-374.
132. Trinchieri, G., Aden, D. & Knowles, B. (1976), "Cell mediated cytotoxicity to SV40 specific tumor associated antigens", Nature. 261, 312-314.
133. Udagawa, T., Fernandez, A., Achilles, E., Folkrnan, J. & D"Arnato, R. (2002), "Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy", FASEB J. 16(11), 1361-1370.
134. Uhr, J. & Marches, R. (2001), "Dormancy in a model of murine B cell lymphoma", Seminars in Cancer Biology 11, 277-283.
135. Uhr, J., Tuckur, T., May, R., H.Siu & Vitetta, E. (1991), "Cancer dormancy: Studies of the murine BCL lymphoma", Cancer Res. (Suppl.) 51, 5045s-5053s.
136. van Blitterswijk, W. (1988), "Structural basis and physiological control of membrane uidity in normal and tumor cells", Subcellular Biochemistry 13, 393-413.
137. van Uriel, W., Kenter, G., Fleuren, G. et al. (1999), "Immunotherapeutic strategies for cervical squamous carcinoma", Hematol. Oncol. Clin. North Am. 13(1), 259-273.
138. Vaughan, H. (1914), "Cancer vaccine and anti-cancer globulin as an aid in the surgical treatment of malignancy", J. Am. Med. Ass. 63, 1258-1268.
139. Webb, S., Sherratt, J. & Fish, R. (2002), "Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology", Mathematical Biosciences 179, 113-129.
140. Wheelock, E.,Weinhold, K. & Levich, J. (1981), "The tumour dormant state", Adv. Cancer Res. 34, 107-140.
141. Wilson, K. & Lord, E. (1987), "Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids", Brit. J. Cancer 55, 141-146.